| Title |
Cell Therapy for Multiple Sclerosis
|
|---|---|
| Published in |
CNS Drugs, April 2017
|
| DOI | 10.1007/s40263-017-0429-9 |
| Pubmed ID | |
| Authors |
Pamela Sarkar, Claire M. Rice, Neil J. Scolding |
| Abstract |
Cell therapy is considered a promising potential treatment for multiple sclerosis, perhaps particularly for the progressive form of the disease for which there are currently no useful treatments. Over the past two decades or more, much progress has been made in understanding the biology of MS and in the experimental development of cell therapy for this disease. Three quite distinct forms of cell therapy are currently being pursued. The first seeks to use stem cells to replace damaged myelin-forming oligodendrocytes within the CNS; the second aims, in effect, to replace the individual's misfunctioning immune system, making use of haematopoietic stem cells; and the third seeks to utilise endogenous stem cell populations by mobilisation with or without in vitro expansion, exploiting their various reparative and neuroprotective properties. In this article we review progress in these three separate areas, summarising the experimental background and clinical progress thus far made. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 80 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 16% |
| Student > Bachelor | 11 | 14% |
| Student > Ph. D. Student | 10 | 12% |
| Researcher | 8 | 10% |
| Professor | 4 | 5% |
| Other | 17 | 21% |
| Unknown | 18 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 13 | 16% |
| Medicine and Dentistry | 13 | 16% |
| Neuroscience | 7 | 9% |
| Agricultural and Biological Sciences | 6 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Other | 12 | 15% |
| Unknown | 25 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2017.
All research outputs
#18,541,268
of 22,963,381 outputs
Outputs from CNS Drugs
#1,176
of 1,313 outputs
Outputs of similar age
#235,850
of 310,129 outputs
Outputs of similar age from CNS Drugs
#13
of 18 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,313 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,129 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.